NCT07763080

Brief Summary

Reverse Fly Exercise On Supraspinatus Tendinitis In Patients Receiving Aromatase Inhibitors Therapy After Mastectomy

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
9mo left

Started Aug 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Aug 2026Jul 2027

First Submitted

Initial submission to the registry

August 5, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

August 13, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

August 18, 2026

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 11, 2027

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 11, 2027

Last Updated

August 19, 2026

Status Verified

August 1, 2026

Enrollment Period

9 months

First QC Date

August 5, 2026

Last Update Submit

August 18, 2026

Conditions

Keywords

MastectomyAromatase inhibitors therapy

Outcome Measures

Primary Outcomes (2)

  • Supraspinatus Tendon Thickness

    Using Dynamic ultrasonography for measuring

    Before 1st physical therapy session And after 8 weeks of regular 3 session per week of physical therapy

  • Functional ability

    By Quik DASH Questionnaire

    Before 1st physical therapy session And after 8 weeks of regular 3 sessions/week of physical therapy

Study Arms (2)

Patients will receieve Reverse fly excercise

EXPERIMENTAL

This group will include 20 patients who will receive after 3:6 weeks from starting aromatase inhibitor the reverse fly exercise , in additions Traditional treatment for tendonitis post mastectomy and their medical treatment. (physiotherapeutic treatments 3 times a week for 8 weeks , including , (pendulum ex , soft tissue release , stretching ex., strengthening ex. and ROM ex.) and their medical treatment.

Other: Reverse fly excercise

Control group

OTHER

This group includes 20 patients who will receive the traditional physical therapy program (pendulum ex , soft tissue release, stretching ex., strengthening ex. and ROM ex.) and their medical treatment ,3 times a week for 8 weeks. 1.2 Criteria for the patient selection:

Other: Control group

Interventions

The procedure Stand with feet shoulder width apart while holding a dumbbell in each hand Flex the hips and knees slightly leaning the trunk forward while maintaining a neutral spine Allow the arms to hang perpendicular to the floor with elbows slightly flexed Horizontally abduct the shoulders by lifting the arms laterally until they are level with the shoulders Retract the scapulae at the top of the movement without elevating the shoulders Lower the arms slowly and with control back to the starting position Repeat for the desired number of repetitions

Patients will receieve Reverse fly excercise

This group includes 20 patients who will receive the traditional physical therapy program (pendulum ex , soft tissue release, stretching ex., strengthening ex. and ROM ex.) and their medical treatment ,3 times a week for 8 weeks. 1.2 Criteria for the patient selection:

Control group

Eligibility Criteria

Age50 Years - 70 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale Patient after mastectomy and receiving aromatase inhibitors therapy for 3:6 weeks before starting physical therapy
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age range between 50:70 years.
  • Female patients participate in the study.
  • All patients with unilateral mastectomy.
  • Patients who receiving aromatase inhibitors treatment.
  • All patients will enroll in this study with have their informed consent.

You may not qualify if:

  • Patients have Metastases
  • Patients with Lymphedema
  • Patients with Rheumatoid arthritis
  • Patients have Neurological deficits (stroke, Parkinsonism)
  • Patients with Psychological disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Cancer Institute(NCI)

Cairo, Egypt

RECRUITING

Related Publications (3)

  • Jatan N, Talo S, Azar AJ, Adrian TE, Kellett CF. Mechanisms and biomarkers for musculoskeletal signs and symptoms in patients treated with aromatase inhibitors: A comprehensive systematic review. Cancer Treat Rev. 2026 Feb;143:103075. doi: 10.1016/j.ctrv.2025.103075. Epub 2026 Jan 1.

    PMID: 41506128BACKGROUND
  • Kaidar-Person O, Poortmans P, Offersen BV, Siesling S, Sklair-Levy M, Meattini I, de Ruysscher D, Kuhn T, Boersma LJ. Spatial location of local recurrences after mastectomy: a systematic review. Breast Cancer Res Treat. 2020 Sep;183(2):263-273. doi: 10.1007/s10549-020-05774-4. Epub 2020 Jul 13.

    PMID: 32661665BACKGROUND
  • Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.

    PMID: 34503097BACKGROUND

Related Links

MeSH Terms

Interventions

Control Groups

Intervention Hierarchy (Ancestors)

Epidemiologic Research DesignEpidemiologic MethodsInvestigative TechniquesResearch DesignMethods

Central Study Contacts

Nourhan Ahmed Mahmoud Souliman, Master degree

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: RCT study
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Asisstance lecturer of physical therapy

Study Record Dates

First Submitted

August 5, 2026

First Posted

August 13, 2026

Study Start

August 18, 2026

Primary Completion (Estimated)

May 11, 2027

Study Completion (Estimated)

July 11, 2027

Last Updated

August 19, 2026

Record last verified: 2026-08

Locations